Condition: Solid Tumor · Advanced Solid Tumor · Sponsor: Pyxis Oncology, Inc
The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with recurrent/metastatic (R/M) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.
This description comes directly from the study's public registry record.
Pyxis Oncology Clinical Trials Team · (339) 545 8252 · clinicaltrials@pyxisoncology.com
Always discuss trial participation with your own doctor first.
| HonorHealth Research Institute | Scottsdale, Arizona, United States | Recruiting |
| Ronald Reagan UCLA Medical Center | Los Angeles, California, United States | Recruiting |
| SCRI - HealthOne Denver | Denver, Colorado, United States | Recruiting |
| SCRI - Florida Cancer Specialists | Sarasota, Florida, United States | Recruiting |
| Winship Cancer Institute, Emory University | Atlanta, Georgia, United States | Recruiting |
| University of Chicago Medicine | Chicago, Illinois, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Washington University School of Medicine | St Louis, Missouri, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| University of Cincinnati Medical Center | Cincinnati, Ohio, United States | Recruiting |
| University of Pennsylvania, Abramson Cancer Center | Philadelphia, Pennsylvania, United States | Recruiting |
+ 17 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05720117